FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome

FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome

Source: 
CP Wire
snippet: 
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced on 5/11/18 that the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of Waylivra (volanesorsen) for the treatment of people with familial chylomicronemia syndrome (FCS).